Arsanis and X4 Pharmaceuticals Agree to Merger

CAMBRIDGE, Mass. and WALTHAM, Mass. and VIENNA, Austria, Nov. 27, 2018 (GLOBE NEWSWIRE) — Arsanis, Inc. (Nasdaq: ASNS) and privately-held X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer, today announced that they have entered into a definitive merger agreement under which X4 Pharmaceuticals is expected to merge with a wholly-owned subsidiary of Arsanis in an all-stock transaction. The merger would result in a combined company operating under the X4 Pharmaceuticals name that will focus on the development and commercialization of X4’s lead product candidate, X4P-001, and the advancement of X4’s pipeline of treatments for rare diseases of the immune system and rare cancers.

This entry was posted in Recent Development News: Q4 - 2018, Recent Developments. Bookmark the permalink.
Read Full Article »